How can I explain to a patient with a prior history of gastric intestinal metaplasia that a recent endoscopic gastric biopsy was negative for intestinal metaplasia, yet they may still have the condition and require surveillance?

Explaining Negative Biopsy Results in a Patient with Prior Gastric Intestinal Metaplasia

Even though your recent endoscopy biopsy did not show intestinal metaplasia, you likely still have this condition somewhere in your stomach, and continued surveillance remains important for your safety. 1

Why the Biopsy Can Be Negative Despite Having GIM

Gastric intestinal metaplasia (GIM) is patchy and unevenly distributed throughout the stomach—it doesn't affect every area uniformly. Here's what you need to understand:

The Sampling Challenge

• GIM is not uniform: The condition appears in scattered patches across the stomach lining, particularly in the antrum (lower stomach) and body (middle stomach) 1
• Biopsies sample only tiny areas: Even with a systematic biopsy protocol taking samples from multiple locations, we're examining less than 1% of your total stomach surface
• Metaplasia can be missed: A negative biopsy doesn't mean GIM has disappeared—it may simply mean the biopsies didn't happen to sample the exact spots where metaplasia exists 1

Why This Matters for Your Care

The 2020 AGA guidelines explicitly recognize this limitation and suggest against routine short-interval repeat endoscopy specifically because of concerns about the completeness of baseline endoscopy 1. However, this doesn't mean you don't have GIM—it means we need to approach surveillance strategically.

Your Ongoing Risk and Surveillance Plan

You Still Require Surveillance Because:

Based on your documented history of GIM, you remain at increased risk for gastric cancer progression 1. The key risk factors that determine your surveillance intensity include:

• Extent of your previous GIM: Was it limited to one area (antrum only) or present in both antrum and body (extensive)?
• Type of GIM: Was it incomplete (higher risk) versus complete (lower risk)?
• Family history: Do you have a first-degree relative with gastric cancer?
• Your ethnic background: Are you from a high-risk population (Asian, Hispanic, or immigrant from high gastric cancer incidence region)?
• H. pylori status: Have you been tested and successfully treated? 1

Recommended Surveillance Strategy

For patients with previously documented GIM, particularly if extensive (both antrum and body), incomplete type, or with family history of gastric cancer, surveillance endoscopy should be performed every 3 years 1, 2. The 2025 AGA Clinical Practice Update reinforces this approach 3.

More specifically:

• Extensive GIM or incomplete GIM with risk factors: Surveillance every 3 years 1, 2
• Limited GIM (antrum only) without other risk factors: Surveillance may not be necessary, but this requires shared decision-making 1
• Multiple risk factors present: Consider surveillance intervals as short as 1-2 years 1

Critical Next Steps

1. Ensure H. pylori Has Been Eradicated

Testing and eradicating H. pylori is a strong recommendation (not optional) for all patients with GIM 1. This is the single most important intervention to reduce your gastric cancer risk. If you haven't had eradication confirmed with a test-of-cure, this must be done.

2. Optimize Your Next Endoscopy Quality

When you return for surveillance, the endoscopy should include:

• High-definition endoscopy with image-enhanced techniques (narrow-band imaging or similar technology) 3, 2
• Systematic biopsies: Minimum 5 biopsies—2 from antrum/incisura, 2 from corpus, placed in separately labeled jars 1, 3
• Adequate examination time: At least 7 minutes of careful mucosal inspection 4
• Targeted biopsies of any suspicious areas in addition to the systematic protocol 3

3. Consider Repeat Endoscopy Within 1 Year If:

You may benefit from a shorter-interval repeat endoscopy (within 1 year) for better risk stratification if: 1

• You have concerns about the completeness of your recent endoscopy
• You have multiple high-risk features (family history, high-risk ethnicity, extensive or incomplete GIM on prior biopsies)
• The recent endoscopy did not follow a systematic biopsy protocol

Common Pitfalls to Avoid

Don't Assume GIM Has "Gone Away"

The absence of GIM on a single set of biopsies does not mean regression has occurred. True regression of GIM after H. pylori eradication is possible but uncommon, and even when it occurs, cancer risk remains elevated 5, 4.

Don't Skip Surveillance Based on One Negative Biopsy

The 2020 AGA guidelines base surveillance recommendations on your highest-risk features documented at any time, not just your most recent biopsy 1. Your prior diagnosis of GIM establishes you as someone who needs ongoing monitoring.

Ensure Proper Documentation

Work with your gastroenterologist to clarify:

• The extent of your previous GIM (limited vs. extensive)
• The histologic subtype if documented (complete vs. incomplete)
• Your H. pylori status and eradication confirmation
• Your family history and ethnic background

This information determines your personalized surveillance interval.

The Bottom Line

Your negative biopsy is reassuring in that it shows no dysplasia or cancer, but it does not eliminate your need for surveillance. GIM is a field defect—once present, the stomach lining remains at increased risk even if individual biopsies don't capture metaplastic areas. Your surveillance plan should be based on your cumulative risk profile, not a single biopsy result. Continue with guideline-directed surveillance every 3 years (or more frequently if you have multiple risk factors), ensure H. pylori eradication, and make certain future endoscopies use high-quality technique with systematic biopsies 1, 3, 2.